stilbenes and Constriction--Pathologic

The association of meatal stenosis with age at circumcision is controversial. We noticed a high rate of meatal stenosis in a region where early circumcision is traditional. The aim of this study is to compare the age at circumcision between boys with or without meatal stenosis.. After ethical approval, families of children with meatal stenosis were questioned about age at circumcision and reason for circumcision. Control group consisted of patients with diagnoses other than penile abnormalities, a normal urethral meatus, and having no symptoms about urination. Patients with a history of therapeutic circumcision were excluded from the study.. Between November 2016 and November 2020, 115 patients with meatal stenosis were admitted. All were corrected with ventral meatotomy under general anesthesia. Median age at circumcision was 3 (min:0-max:111) monthsand age at admission was 74 (min:22-max:194) months. Control group consisted of 205 boys. Median age at circumcision was 5 (min:0-max:122) months and age at admission was 96 (13-202) months. There was a statistically significant difference between groups in terms of age at circumcision (p=0.024) but none for age at admission (p=0.356). There was a twofold increase in the meatal stenosis rate (39% vs. 23%) if circumcision was performed before age one (p=0.018). There was no difference between the patients circumcised in the newborn period and later (38% vs 36%, p=0.778).. Our study supports the previous reports suggesting a relation of risk for meatal stenosis and age at circumcision and presents data that age one might be a cutoff for this risk.

Topics: Child; Circumcision, Male; Constriction, Pathologic; Hospitalization; Humans; Infant; Infant, Newborn; Male; Stilbenes

The aim of this study was to investigate the effects of resveratrol (RVT) in chronic constriction injury (CCI) of sciatic nerve by behavioral, histomorphological and immunohistochemical evaluations in rats. In this study, male Wistar rats were divided into three groups: sham (n=7), CCI+saline (n=7) and CCI+RVT (n=7). After inducing CCI, treatment with 10mg/kg/day of RVT or saline for 14 days was given. Locomotor function was assessed with rota-rod and open field tests. Morphologic alterations of sciatic nerve were assessed histologically by light and electron microscopy. Immunohistochemistry for insulin-like growth factor-1 (IGF-1) were performed. RVT treatment prevented motor impairment and histomorphological alterations caused by chronic constriction injury of sciatic nerve. IGF-1 immunoreactivity was significantly higher in RVT treated group then CCI induced group and positive correlated with morphometric parameters. These results indicate that RVT may reduce CCI induced damage and this effect may be mediated through the restoration of IGF-1 immunoreactivity.

Topics: Animals; Antioxidants; Chronic Disease; Constriction, Pathologic; Immunohistochemistry; Insulin-Like Growth Factor I; Male; Motor Activity; Neuroprotective Agents; Peripheral Nerve Injuries; Rats, Wistar; Resveratrol; Sciatic Nerve; Stilbenes

Patients suffering from chronic neuropathic pain are at high risk of co-morbid depression, which burdens healthcare. This work aimed to investigate the effects of resveratrol, a phenolic monomer enriched in red wine and grapes, on pain-related and depressive-like behaviors in mice with mononeuropathy, and explored the mechanism(s). Mice received chronic constriction injury (CCI) of sciatic nerves, and sequentially developed pain-related and depressive-like behaviors, as evidenced by sensory hypersensitivity (thermal hyperalgesia in Hargreaves test and mechanical allodynia in von Frey test) and behavioral despair (prolonged immobility time in forced swim test). Chronic treatment of neuropathic mice with resveratrol (30 mg/kg, p.o., twice per day for three weeks) normalized their thermal hyperalgesia (but not mechanical allodynia) and depressive-like behaviors, and these actions were abolished by chemical depletion of central serotonin (5-HT) but potentiated by co-treatment with 5-HTP, a precursor of 5-HT. The anti-hyperalgesia and anti-depression exerted by resveratrol may be pharmacologically segregated, since intrathecal (i.t.) and intracerebroventricular (i.c.v.) injection of methysergide, a non-selective 5-HT receptor antagonist, separately abrogated the two actions. Furthermore, the antihyperalgesic action of resveratrol was preferentially counteracted by co-administration of the 5-HT7 receptor antagonist SB-258719, while the anti-depression was abrogated by 5-HT1A receptor antagonist WAY-100635. These results confirm that chronic resveratrol administration exerts curative-like effects on thermal hyperalgesia and co-morbid depressive-like behaviors in mice with mononeuropathy. Spinal and supraspinal serotonergic systems (coupled with 5-HT7 and 5-HT1A receptors, respectively) are differentially responsible for the antihyperalgesic and antidepressant-like properties of resveratrol.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Brain; Comorbidity; Constriction, Pathologic; Depression; Disease Models, Animal; Hot Temperature; Hyperalgesia; Male; Mice, Inbred C57BL; Neuralgia; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin; Resveratrol; Sciatic Neuropathy; Spinal Cord; Stilbenes; Touch

Late-term thrombosis associated with drug-eluting stents may be due to the non-selective actions of antimitogenic drugs on endothelial cells, leading to delayed vascular healing after stenting angioplasty. Currently, there is a need for stent-based therapies that can both attenuate neointimal hyperplasia and promote re-endothelialization. The aim of this study was to compare the effects of a resveratrol (R)- and quercetin (Q)-eluting stent with that of a bare metal stent (BMS) on neointimal hyperplasia and re-endothelialization in a rat model of arterial angioplasty and stenting. Miniature stents (2.5×1.25mm) were sprayed with nanocomposite coatings containing two concentrations of R:Q (50:25μg/cm(2) (RQ1) or 150:75μg/cm(2) (RQ2)). The stents were deployed into the common carotid artery of rats and their impact on vascular remodeling was compared to that of BMS. Luminal stenosis in arteries stented with RQ2-eluting stents was reduced by 64.6% (p<0.05) compared to arteries stented with BMS. Accompanying this effect was a 59.8% reduction in macrophage infiltration (p<0.05). There were no differences found between RQ1 and BMS. Finally, the RQ2-coated stent accelerated re-endothelialization by 50% compared with BMS (p<0.05). Thus, compared with BMS, local delivery of R and Q from a stent platform significantly reduced in-stent stenosis, while promoting re-endothelialization. These data suggest that R and Q may be favorable candidates for novel stent coatings, potentially reducing the risk of late thrombosis associated with drug-eluting stents.

Topics: Angioplasty; Animals; Antimitotic Agents; Cell Proliferation; Constriction, Pathologic; Drug-Eluting Stents; Endothelium, Vascular; Female; Hyperplasia; Male; Nanocomposites; Neointima; Quercetin; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes